GeoVax

Read more
David A. Dodd's photo - Chairman & CEO of GeoVax

Chairman & CEO

David A. Dodd

CEO Approval Rating

86/100

Founded:

2001

Status:

PublicIndependent CompanyNASDAQGOVX

GEOVAX TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

David A. Dodd

Chairman & CEO

- -
7
$27M
$1.2M
View Profile
1

Kenneth A. Berlin

President & CEO

76/100
35
$83.6M
$1.9M
View Profile
2

Franz-Werner Haas

CEO

83/100
554
$1.5B
$21.4M
View Profile
3

Ryan Spencer

CEO

89/100
249
$563.3M
$119M
View Profile
4

Stephen T. Isaacs

Chairman & CEO

87/100
105
$239.6M
$ < 1M
View Profile
5

Weidong Yin

Chairman & CEO

90/100
1,959
$626.5M
$510.6M
View Profile
6

Frank R. Jones

Chairman & CEO

88/100
15
$21.4M
$7M
View Profile
7

Xuefeng Yu

Chairman & CEO

89/100
740
$226M
$284.1M
View Profile
8

Grant E. Pickering

President & CEO

68/100
80
$15.9M
$2M
View Profile
9

Michael Chambers

Interim-CEO

70/100
10
$2M
$2M
View Profile
10

Harold Smith

President & CEO

73/100
11
$3.6M
$5M
View Profile

Missing a competitor? Contribute!

Advaxis is seen as one of GeoVax's top competitors. Advaxis's headquarters is in Monmouth Junction, New Jersey, and was founded in 2002. Like GeoVax, Advaxis also works within the Biotechnology industry. Advaxis generates 266% of GeoVax's revenue.

CureVac is one of GeoVax's top rivals. CureVac was founded in 2000, and its headquarters is in Tubingen, Baden-Württemberg. Like GeoVax, CureVac also works within the Biotechnology field. CureVac has 547 more employees than GeoVax.

Dynavax is GeoVax's #3 rival. Dynavax is a Public company that was founded in 1996 in Emeryville, California. Like GeoVax, Dynavax also competes in the Biotechnology sector. Compared to GeoVax, Dynavax has 238 more employees.

GeoVax Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.2M

GeoVax's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 86.8M. Over the last four quarters, GeoVax's revenue has decreased by 74.9%. Specifically, in Q1 2021's revenue was $ < 1M; in Q4 2020, it was $ < 1M; in Q3 2020, it was $ < 1M; in Q2 2020, GeoVax's revenue was $ < 1M.

GeoVax Acquisitions

No recent acquisitions found related to GeoVax

GeoVax Funding History

Since GeoVax was founded in 2001, it has participated in 9 rounds of funding. In total GeoVax has raised $27.0M. GeoVax's last funding round was on Feb 2021 for a total of $10.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Unattributed
Feb 2021
$10.3M
-
Private Placement
Jun 2020
$1.2M
-
Private Placement
Jul 2019
$700K
-
Private Placement
May 2017
$1M
-
Private Placement
Dec 2013
$1.6M
-

Since GeoVax was founded in 2001, it has participated in 9 rounds of funding. In total GeoVax has raised $27.0M. GeoVax's last funding round was on Feb 2021 for a total of $10.3M

GeoVax Investments

No recent investments found related to GeoVax

GeoVax News

June 7, 2021MarketScreener

GeoVax to Present at 2021 BIO Digital

(marketscreener.com) GeoVax Chairman & CEO to Participate in Vaccine Panel Discussion ATLANTA, GA, Ju... See more »
May 11, 2021FinanzNachrichten

GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit

Atlanta, Georgia--(Newsfile Corp. - May 11, 2021) - GeoVax Labs, Inc. (NASDAQ: GOVX) today announced ... See more »
May 6, 2021Markets Insider

GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021

GeoVax Chairman & CEO David Dodd to Participate in Panel DiscussionATLANTA, GA, May 06, 2021 (GLOBE N... See more »
March 24, 2021MarketScreener

GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update

(marketscreener.com) COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains Immuno-Oncolog... See more »
March 17, 2021Markets Insider

GeoVax to Participate in Benzinga Biotech Small Cap Conference

GeoVax Chairman & CEO David Dodd to Present Corporate OverviewGeoVax CSO, Mark Newman, PhD, to Partic... See more »
March 15, 2021Markets Insider

GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update

Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern TimeATLANTA, GA, March 15, 2021 ... See more »

GeoVax Press Releases

April 1, 2021centralcharts

GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent

Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide Atlanta, GA, April 01, 2... See more »
March 10, 2021NewMediaWire

GeoVax to Participate in Maxim Group's Inaugural Emerging Growth Virtual Conference

GeoVax Chairman & CEO David Dodd to Present Corporate OverviewGeoVax CSO, Mark Newman, PhD, to Partic... See more »
March 3, 2021NewMediaWire

GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference

Virtual Conference to be Held March 9-10, 2021Atlanta, GA - (NewMediaWire) - March 03, 2021 - GeoVax ... See more »
March 1, 2021GlobalNewswire

Registration Now Open For Tribe Public's Webinar Event "Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond" Featuring GeoVax's CEO & CFO On March 3, 2021

Meet with GeoVax CEO David Dodd & CFO Mark Reynolds who will Deliver a Presentation Titled "Advancing... See more »
January 5, 2021NewMediaWire

GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

GeoVax Also Participating in [email protected] During "J.P. Morgan Week 2021"Atlanta, GA - (NewMediaWire) - Jan... See more »
October 28, 2020NewMediaWire

GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by Outsourced Pharma

Atlanta, GA - (NewMediaWire) - October 28, 2020 - GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) ("GeoVax"... See more »
September 25, 2020centralcharts

GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split

ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX... See more »

GeoVax Videos

Social Media

GeoVax Headquarters

1900 Lake Park Drive Suite 380

Smyrna, Georgia30080

678-384-7220

Driving Directions »

Trending Companies

GeoVax Summary

ABOUT

Overview

GeoVax is a Georgia-based biopharmaceutical company that develops and commercializes immunotherapies for the treatment of cancer. GeoVax was founded in 2001. GeoVax's headquarters is located in Smyrna, Georgia, USA 30080. It has raised 27.0M in 9 roun...

CEO

GeoVax's Chairman & CEO, David A. Dodd, currently has an approval rating of 86%. GeoVax's primary competitors are Advaxis, CureVac & Dynavax.

Website

geovax.com

Frequently Asked Questions about GeoVax

  1. When was GeoVax founded?

    GeoVax was founded in 2001
  2. Who is GeoVax's CEO?

    GeoVax's CEO is David A. Dodd
  3. How much revenue does GeoVax generate?

    GeoVax generates $1.2M in revenue
  4. How much funding does GeoVax have?

    GeoVax has historically raised $27M in funding
  1. Where is GeoVax's headquarters?

    GeoVax's headquarters is in Smyrna Georgia, USA
  2. How many employees does GeoVax have?

    GeoVax has 7 employees
  3. What sector does GeoVax operate in?

    GeoVax is in Biotechnology, Pharmaceuticals
  4. Who are GeoVax's competitors?

    GeoVax's top competitors are Advaxis, CureVac, Dynavax